F16IL2
AssetProtein or enzyme
Antibody-cytokine fusion protein targeting the A1 domain of tenascin-C coupled with interleukin-2.
- Stage
- Phase 3
- Modality
- Protein or enzyme
- Target
- Inflammation
- Indications
- 6
- Trials
- 1,321
- Developers
- 1
Indications
6Soft tissue sarcoma
Phase 3UNKNOWNNCT04650984clinicaltrials.gov7 Oct 2026
Leiomyosarcoma
Phase 2UNKNOWNNCT03420014clinicaltrials.gov7 Oct 2026
Advanced solid tumor
Phase 1TERMINATEDNCT01131364clinicaltrials.gov7 Oct 2026
3 more
- Targets and what it contains5
- Owner and partners1
- Trials1,321
- Evidence for its targets3
- Competitors11
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 5 sources